XuanwuH Acute Ischemic Stroke Registry
Launched by XUANWU HOSPITAL, BEIJING · Jan 12, 2022
Trial Information
Current as of June 18, 2025
Recruiting
Keywords
ClinConnect Summary
The XuanwuH Acute Ischemic Stroke Registry is a study focused on understanding how patients with acute ischemic stroke—when a blood clot blocks blood flow to the brain—are diagnosed and treated at Xuanwu Hospital in China. The researchers aim to collect important information about patients' medical backgrounds, the treatments they receive, and their recovery over a period of up to 90 days after their stroke. This study is designed to improve the hospital's "green channel," which is a fast-track process for treating stroke patients, ensuring they get the best care as quickly as possible.
To be eligible for this study, participants must be at least 18 years old and have been clinically diagnosed with an acute ischemic stroke or a transient ischemic attack (TIA), which is a temporary blockage that may lead to a stroke. The study is currently recruiting participants, and anyone who meets these criteria and receives care in the stroke "green channel" at Xuanwu Hospital may be invited to take part. By joining the study, participants can help researchers better understand stroke care, which could lead to improved treatment and outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of acute ischemic stroke or transient ischemic attack(TIA)
- • Age \>18 years
- • Ethic approval in process
- • Receiving assessment in stroke "green channel" of Xuanwu Hospital
- Exclusion Criteria:
- • Non-acute ischemic stroke
About Xuanwu Hospital, Beijing
Xuanwu Hospital, located in Beijing, is a leading clinical research institution renowned for its commitment to advancing medical knowledge and improving patient care. Affiliated with Capital Medical University, the hospital specializes in neurology and rehabilitation, providing a robust framework for innovative clinical trials. With a multidisciplinary team of experienced researchers and healthcare professionals, Xuanwu Hospital focuses on conducting high-quality, ethically sound studies that aim to explore new treatment modalities and enhance therapeutic outcomes. Through its dedication to research excellence and patient-centered approaches, Xuanwu Hospital plays a pivotal role in the advancement of healthcare solutions both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
qingfeng Ma, MD
Study Chair
Xuanwu Hospital, Beijing
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials